1-cyclohexyl-3-hexyl urea

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 1-cyclohexyl-3-hexyl urea
• 英文别名: 1-cyclohexyl-3-hexyl-urea；N-cyclohexyl-N'-hexylurea；1-cyclohexyl-3-hexylurea
• 化学式: C₁₃H₂₆N₂O
• 分子量: 226.362
• InChiKey: QZDGGCAVTQECFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  正己胺 、 环己基异氰酸酯 生成 1-cyclohexyl-3-hexyl urea
  参考文献：
  名称：

  合成 尿素在不存在的情况下来自胺和CO 2的衍生物催化剂 和 溶剂

  摘要：

  尿素 从 脂肪族伯胺用CO 2在没有任何催化剂， 有机的 溶剂或其他添加剂。为了优化反应条件，研究了温度，压力，胺浓度，反应时间等实验变量。在优化的条件下获得了令人满意的产量，与存在下的可比性相当。催化剂 和 溶剂。对反应机理的初步研究表明，烷基氨基甲酸烷基铵迅速形成了中间体，然后通过分子内脱水形成了最终产物。

  DOI：

  10.1039/c0gc00059k

文献信息

• Nonpeptide agonists and antagonists of vasopressin receptors
  申请人：——

  公开号：US20020128208A1

  公开（公告）日：2002-09-12

  The disclosed invention is a composition agonists and/or antagonists of V 2 , V 1a or both receptors, in a host, including animals, and especially humans, using a small molecule or its pharmaceutically acceptable salt or prodrug.

  所披露的发明是在宿主中，包括动物，尤其是人类，使用小分子或其药用盐或前药，制备V2、V1a或两者受体的激动剂和/或拮抗剂的组合物。
• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION
  申请人：Hammock D. Bruce

  公开号：US20070117782A1

  公开（公告）日：2007-05-24

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

  本发明提供了一些化合物，用于治疗高血压的治疗应用中，抑制环氧水解酶。实施本发明的优选化合物类别具有由式1所示的结构，其中Z为氧或硫，W为碳、磷或硫，X和Y各自独立地为氮、氧或硫，而X还可以是碳，R1-R4中至少有一个是氢，当X为氮时，R2为氢，但当X为硫或氧时，R2不存在，当Y为氮时，R4为氢，但当Y为硫或氧时，R4不存在，而R1和R3各自独立地为C1-C20取代或未取代的烷基、环烷基、芳基、酰基或杂环基。
• Structural refinement of inhibitors of urea-based soluble epoxide hydrolases
  作者：Christophe Morisseau、Marvin H. Goodrow、John W. Newman、Craig E. Wheelock、Deanna L. Dowdy、Bruce D. Hammock

  DOI：10.1016/s0006-2952(02)00952-8

  日期：2002.5

  The soluble epoxide hydrolase (sEH) is involved in the metabolism of arachidonic, linoleic, and other fatty acid epoxides, endogenous chemical mediators that play an important role in blood pressure regulation and inflammation. 1,3-Disubstituted ureas, carbamates, and amides are new potent and stable inhibitors of sEH. However, the poor solubility of the lead compounds limits their use. Inhibitor structure-activity relationships were investigated to better define the structural requirements for inhibition and to identify points in the molecular topography that could accept polar groups without diminishing inhibition potency. Results indicate that lipophilicity is an important factor controlling inhibitor potency. Polar groups could be incorporated into one of the alkyl groups without loss of activity if they were placed at a sufficient distance from the urea function. The resulting compounds had a 2-fold higher water solubility. These findings will facilitate the rational design and optimization of sEH inhibitors with better physical properties. (C) 2002 Published by Elsevier Science Inc.
• Urea derivatives for the protection of stem cells
  申请人：Symrise AG

  公开号：EP2862852B1

  公开（公告）日：2018-07-04
• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION
  申请人：Kroetz Deanna L.

  公开号：US20110245331A1

  公开（公告）日：2011-10-06

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.